Sign Up - Nice News
Nice News sends a daily digest to your inbox each morning with only positive news stories. Wake up with a more optimistic mindset and start your day inspired.
Mission - Nice News
We are on a mission to re-imagine how people interact with their daily news feed. Nice News launched in February 2022 as an email digest that could be read over a cup of coffee. It has since grown into a safe space to catch up on uplifting news that might otherwise be missed.
Nice News Amassed Over 750K Subscribers in 2 Years — And It …
Mar 4, 2024 · Nice News is celebrating two years of spreading positivity in the inbox. In that time, the newsletter has amassed a loyal following of more than 750,000 subscribers who are interested in the brighter side of news — a necessity in the current media landscape.
Posts | Nice News
Nice News is a positive news platform centered around a daily news digest sent to your inbox each morning. We filter your news for positivity, bringing stories to the forefront that are often overshadowed by other major headlines.
This Newsletter Amassed Over 750K Subscribers in 2 Years - PR …
Mar 5, 2024 · In honor of its two-year anniversary on Sunday, Nice News launched a website revamp, offering readers new sections like sports and technology, a deeper look at the team behind the morning...
Nice News - LinkedIn
Our mission at Nice News is to share stories that connect, empower, and inspire, showcasing the good that can come when we work together. You’ll find stories about scientific discoveries,...
NICE to Report Q3 Earnings: What's in Store for the Stock?
2 days ago · For the to-be-reported quarter, NICE expects non-GAAP revenues between $676 million and $686 million, indicating 13% year-over-year growth at the midpoint. The Zacks Consensus Estimate for ...
Nice News | Google for Publishers
In 2022, Devlin launched Nice News, a five-minute daily email digest that features a roundup of positive news stories on various topics, including science, health, environment, culture, and...
Sanofi wins appeal in spat with NICE over Sarclisa
1 day ago · The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside Bristol-Myers Squibb/Celgene's Imnovid (pomalidomide) and dexamethasone ...
Nice News - Facebook
Nice News. 20,165 likes · 1,514 talking about this. A daily dose of positivity for your inbox. Join 800K+ readers and start your morning inspired.🌞